Literature DB >> 8361861

Liver disorders in patients receiving chlorpromazine or isoniazid.

L E Derby1, S P Gutthann, H Jick, A D Dean.   

Abstract

Based on information derived from computers and clinical records obtained from general practitioners in the United Kingdom, we estimated the frequency of liver toxicity associated with two known hepatotoxins, chlorpromazine and isoniazid. Among the cohort of 10,502 users of chlorpromazine, 14 had illnesses compatible with drug-induced liver disease, a frequency of 1.3/1000 users (95% Cl 0.8, 2.2). Four presumed cases of the disorder occurred among 921 users of isoniazid, for a frequency of 4/1000 users (95% Cl 1.7, 11.1). This study provides population-based quantification of the frequency of liver disorders associated with the use of these two agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8361861

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

Review 1.  Prevention and management of tuberculosis in HIV positive patients living in countries with a low prevalence of Mycobacterium tuberculosis.

Authors:  M G Brook; R F Miller
Journal:  Genitourin Med       Date:  1996-04

2.  Chlorpromazine-induced hepatotoxicity during inflammation is mediated by TIRAP-dependent signaling pathway in mice.

Authors:  Adarsh Gandhi; Tao Guo; Pranav Shah; Bhagavatula Moorthy; Romi Ghose
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-11       Impact factor: 4.219

3.  Acute and clinically relevant drug-induced liver injury: a population based case-control study.

Authors:  Francisco J de Abajo; Dolores Montero; Mariano Madurga; Luis A García Rodríguez
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

4.  Terfenadine and risk of acute liver disease.

Authors:  M W Myers; H Jick
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

5.  Alterations of liver function test in patients treated with antipsychotics.

Authors:  M Teresa Garcia-Unzueta; Andres Herran; Deirdre Sierra-Biddle; J Antonio Amado; J Luis Vázquez-Barquero; Concepción Alvarez
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

6.  Chlorpromazine-induced perturbations of bile acids and free fatty acids in cholestatic liver injury prevented by the Chinese herbal compound Yin-Chen-Hao-Tang.

Authors:  Qiaoling Yang; Fan Yang; Xiaowen Tang; Lili Ding; Ying Xu; Yinhua Xiong; Zhengtao Wang; Li Yang
Journal:  BMC Complement Altern Med       Date:  2015-04-16       Impact factor: 3.659

7.  Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study.

Authors:  James A Kaye; Jordi Castellsague; Christine L Bui; Brian Calingaert; Lisa J McQuay; Nuria Riera-Guardia; Catherine W Saltus; Scott Quinlan; Crystal N Holick; Peter M Wahl; Kiliana Suzart; Kenneth J Rothman; Mari-Ann Wallander; Susana Perez-Gutthann
Journal:  Pharmacotherapy       Date:  2013-11-05       Impact factor: 4.705

Review 8.  Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.

Authors:  Diogo Telles-Correia; António Barbosa; Helena Cortez-Pinto; Carlos Campos; Nuno B F Rocha; Sérgio Machado
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-02-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.